◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-FOR-NOW HIGH

AF710B

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

A-tier rodent disease-modification data (cognitive deficits + amyloid + tau + neuroinflammation reverted, effect persisted 5 wk post-washout) is mechanistically exciting, BUT (a) zero clinical efficacy data in any cognitive-decline indication, (b) the sister sigma-1-only compound blarcamesine (ANAVEX 2-73) just had its EMA application recommended for refusal Dec 11 2025 — meaningful negative signal for the platform, (c) Phase 2 schizophrenia readout Oct 2025 was a safety primary endpoint with only "encouraging trends" on biomarkers, no efficacy hit, (d) human PK shows a 3.5-hr half-life that argues against simple translation of the rodent pulsed-dosing → 5-week-persistent-effect protocol, (e) research-chem availability is real (MCE, TargetMol) but priced for academic milligram screens, with no community dose, no community subjective base, no COA-verified human-grade vendor. Mechanism interesting; translation thin. Would upgrade to WATCH-LIST → OPTIONAL-ADD if (1) FTD orphan trial reads positive on cognition, or (2) Anavex's own M1-PAM thesis survives the blarcamesine EMA refusal and the sigma-1-platform stops looking like a stumble, or (3) a credible second-source replicates the rat 5-wk-persistence finding.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    No cognition-enhancement evidence in healthy adults. Rodent disease-modification data does not project to a young intact brain — there is no AD pathology to revert in a 20yo athlete. Mechanism-curiosity is real but the platform is stumbling (blarcamesine EMA refusal Dec 2025, Phase 2 schiz hit safety endpoint only). Vendor route is research-chem-only with no community precedent. Re-evaluate when an Alzheimer's or FTD efficacy trial reports on cognition specifically.

  • 30-50, executive maintenance
    SKIP-FOR-NOW

    Same logic — no upside, no protocol, no vendor.

  • 50+, mild cognitive decline
    WATCH-LIST

    This is the demographic the compound is being developed for. If a Phase 2 AD or FTD readout is positive on cognition (not just biomarkers), this becomes interesting *for this group only* — but still not via gray-market sourcing. The right path is clinical-trial enrollment if eligible.

  • Anxiety-prone
    SKIP-FOR-NOW

    No data. Sigma-1 agonism *could* theoretically be anxiolytic (sigma-1 is implicated in stress / antidepressant mechanism — pridopidine, blarcamesine have mixed mood signals), but there is no anxiety-specific human trial.

  • High athletic load, tested status
    SKIP-FOR-NOW

    Not on WADA list (irrelevant for Dylan, who is untested), but no rationale for athletic use.

  • Sleep-disordered
    SKIP-FOR-NOW

    No sleep data either way.

  • Recovery-focused (post-injury, post-illness)
    WATCH-LIST

    The TBI-recovery thesis is mechanistically plausible (sigma-1 agonism reduces neuroinflammation, M1-PAM supports cholinergic recovery in basal-forebrain damage models) but speculative. cerebrolysin is the better current pick for this profile — same thesis, far more clinical data, actually accessible. Revisit AF710B if a TBI trial ever launches.

  • Strength/anabolic-focused
    SKIP-PERMANENT

    (irrelevant mechanism).

▸ Subjective experience (deep)

Largely unknown in humans at any cognitively relevant dose, and there is no community base.

What we know:

  • Phase 1 was safety-uneventful (no published AE detail, but no trial halt)
  • Phase 2 schizophrenia subjects on background antipsychotics tolerated it with no severe TEAEs (this means the compound is not adding gross sedation, EPS, or QTc burden on top of antipsychotics — which is a meaningful negative-finding-as-positive)
  • No reported procholinergic peripheral side effects (no GI, no sweating, no bradycardia in trial reports), consistent with M1 selectivity
  • No psychoactive recreational signal — the compound is being developed as disease-modifying, not as a felt cognitive enhancer

What we don't know:

  • Whether a healthy adult would feel anything at any dose
  • Whether the rodent "cognitive enhancement" signal at 1-30 µg/kg PO maps to a felt human effect or only an objective-test effect
  • Whether sigma-1 agonism produces the same subtle "warm calm + clarity" reported with blarcamesine community-dosing — most reports of which are confounded by its parallel approval status in some jurisdictions and by Anavex stock-promotion echo

This is a non-felt compound by design. Treat any community report claiming "I felt amazing on AF710B" as suspect — vendor confusion (ACD-856, ANAVEX 2-73, AF710B all have similar branding) is more plausible than authentic AF710B subjective experience.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown in humans. Rat data showed persistent effect after washout, which is the opposite of tolerance — suggests structural change, not desensitization. Allosteric M1 PAMs are theoretically less prone to receptor desensitization than orthosteric agonists (one of the design rationales).
  • Recommended cycle: N/A — do not cycle a compound you shouldn't be taking.
  • Reset protocol: N/A.
▸ Stacking deep dive

Synergistic with (theoretical, not validated)

  • cerebrolysin — TrkA/TrkB neurotrophic + M1/sigma-1 chaperone is a clean theoretical pair (different pathways, both pro-survival, both disease-modifying-claim). No data.
  • acd-856 — Trk-PAM amplifies BDNF/NGF signaling; M1-PAM amplifies ACh signaling. Two PAM mechanisms aimed at different transmitter systems with overlapping plasticity outputs (BDNF, ERK, CREB). Theoretically additive on plasticity. No data.
  • citicoline / alpha-GPC — provides ACh substrate; M1-PAM amplifies whatever ACh is produced. Mechanistically clean.

Avoid stacking with

  • Strong serotonergic agents (SSRIs, MAOIs, tramadol, MDMA) — sigma-1 + 5-HT additive risk, theoretical.
  • Donepezil / galantamine / huperzine A — stacking M1-PAM on top of cholinesterase inhibitors is a redundant double-hit on cholinergic signaling and may produce peripheral muscarinic AE that neither alone would. Pick one mechanism.
  • High-dose anticholinergics (diphenhydramine, scopolamine, tricyclic antidepressants) — would functionally cancel the M1-PAM action.

Neutral / safe co-administration (theoretical)

  • Modafinil, bromantane, semax/adamax, BPC-157, NAC, magnesium, omega-3 — no mechanistic conflict.
▸ Drug interactions deep dive
  • CYP profile: Not publicly disclosed in detail. The 2024 Fadiran PK paper would be the primary reference but does not appear to flag a major CYP induction/inhibition signal.
  • M8 metabolite has its own ~6.6-hr half-life and presumably some pharmacological activity — relevant if metabolism is altered.
  • Hormonal contraceptive interactions: Not characterized. Assume unknown.
  • Antipsychotic background therapy: Tolerated in Phase 2 schizophrenia trial — modest evidence the compound doesn't aggressively shift D2/D3/5-HT2A pathway pharmacology.
▸ Pharmacogenomics

No published data. No CYP-specific dosing guidance. No M1 / SIGMAR1 polymorphism subgroup analysis from the Phase 1 or Phase 2 data has been published.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research chemical (academic-grade) MedChemExpress (medchemexpress.com/af710b.html) ~$200-400 / 5-10 mg High (CoA available) Research use only, no human-grade certification, no oral formulation. Geo-restricted in some territories.
Research chemical (academic-grade) TargetMol similar pricing tier High Same caveats — academic screening compound.
Research chemical (racemic) MCE / Benchchem (Rac)-AF710B, CAS 1235733-73-9 ~$150-300 / 10 mg Medium Racemic mix — contains the inactive AF710A enantiomer, NOT what was characterized in the rat efficacy studies. The B-enantiomer is the named active. Avoid the racemate even if cheaper.
Gray-market peptide vendor (typical Russian / Indian peptide sources) None I could find — — AF710B has no community-vendor presence. Kimera Chems, RUPharma, CosmicNootropic do not appear to stock it. The encyclopedia entry that listed Kimera Chems for AF710B is aspirational, not confirmed.
Rx pathway None — — Investigational only — no Rx pathway in any jurisdiction.
Clinical trial enrollment Anavex's FTD / schizophrenia / Alzheimer's trials when active $0 (placebo arm risk) Variable The legitimate access path. Not realistic for Dylan (not in AD/schiz/FTD target population).

Sourcing reality: if you want to handle this molecule, MedChemExpress is the only credible vendor — for a research milligram screen, not for self-administration. There is no human-grade vendor, no oral capsule formulation, no community dose. For practical purposes: not commercially available.

▸ Biomarkers to track (deep)

Don't trial this — but if you did (you shouldn't):

  • Baseline: ADAS-Cog or Cambridge Brain Sciences cognitive battery, hsCRP, IL-6, GFAP (if assayable), serum NfL, basic CMP + CBC, ECG (QTc), HRV (peripheral muscarinic check)
  • During use: Cognitive battery weekly, HR + sweating + GI subjective tracking daily, HRV weekly, GFAP at week 4 + week 12 (mirroring the Phase 2 schiz biomarker)
  • Post-cycle: Cognitive battery at week +1, +4, +8 to test the rat "5-week persistence" claim in human (almost certainly negative in a healthy brain — but it's the only interesting question)
▸ Controversies / open debates Live debate

1. The blarcamesine signal is a real platform-credibility hit

Blarcamesine (ANAVEX 2-73) is the sigma-1-only sister compound. Its Phase 2b/3 in early AD reported (per Anavex) a 38.5% slowing of clinical decline at 50 mg vs placebo on ADAS-Cog13 (p=0.021), and Anavex submitted to EMA Q4 2024. On December 11, 2025, the EMA's CHMP recommended refusal of the marketing application, citing failure to show improvement on both primary outcomes, methodological concerns, and safety questions. Anavex has requested re-examination. This is not just a regulatory skirmish — it's a serious independent scientific reading saying the data does not support efficacy. Since AF710B and blarcamesine share the sigma-1 mechanism and the same sponsor's clinical-trial methodology, this is a meaningful negative read-across for the AF710B program. The encyclopedia's framing of Anavex 2-73 having "failed Phase 3 recently" is essentially correct.

2. The 5-week persistence claim has not been independently replicated outside the Anavex / Fisher orbit

The 2018 Hall et al. paper is the single source for the 5-week post-washout persistence finding. The 2023 follow-up (Sci-Direct S0197458023002257) is from overlapping authorship. AlzPED has curated the data but not independently replicated. A finding this striking should have been replicated by competitor labs by now and has not been. This is a yellow flag for the headline animal claim.

3. M1 PAM as a class — KarXT changed the field but didn't validate AF710B

KarXT (xanomeline-trospium, Cobenfy) was approved Sept 2024 for schizophrenia. It's an orthosteric M1/M4 agonist, not a PAM, and it required co-formulation with peripheral anticholinergic trospium to be tolerable. KarXT's approval validates muscarinic agonism as a clinical schizophrenia mechanism but does not validate the AF710B-specific PAM-only design, and KarXT has the field's monetization and momentum on schizophrenia. AF710B is now competing in a field where KarXT exists, which may explain Anavex's pivot toward FTD as primary indication.

4. Western mechanism-vs-clinical disconnect

This is a recurring pattern in late-stage Alzheimer's: animal data shows disease modification → human trials show modest or null cognition signal. Aducanumab, lecanemab, donanemab all had striking biomarker effects but mixed/modest cognitive effects. AF710B is at risk of repeating the pattern. The fact that the Phase 2 schizophrenia trial highlighted biomarker findings (GFAP) rather than clinical efficacy is the same warning sign in miniature.

5. Encyclopedia accuracy concerns to flag

  • The encyclopedia line "Effects persisted 5 weeks after stopping = true disease-modifying" is sourced correctly to the Hall 2018 paper but overstates external replication. It's one paper, one lab cluster.
  • The encyclopedia line "Sister compound Anavex 2-73 failed Phase 3 recently (concerning context)" — true at the level of EMA outcome (Dec 2025 refusal recommendation), but the company's own framing is positive on Phase 2b/3 data. This is the kind of disagreement worth carrying forward in the wiki.
  • The encyclopedia / vendor mapping pointing AF710B sourcing at Kimera Chems is not verified — I could not confirm Kimera stocks AF710B. The credible vendors are MedChemExpress / TargetMol, both research-grade.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW (HIGH confidence). Mechanism interesting (M1 PAM + sigma-1, dual disease-modifying claim), animal data A-tier but not externally replicated, human cognition data zero, Phase 2 schiz readout was safety-only with biomarker trends, sister compound blarcamesine got EMA refusal recommendation Dec 2025 hitting platform credibility, no community vendor route, no defensible self-trial dose. Re-eval triggers: (1) FTD efficacy trial reads positive on cognition, (2) blarcamesine re-examination overturns EMA refusal, (3) independent replication of rat 5-wk persistence finding, (4) credible human-grade vendor emerges with COA + community subjective base.
▸ Open questions / gaps Open
  • Is the rat 5-week persistence a real disease-modifying signal, a peculiarity of the McGill-R-Thy1-APP model, or partial measurement artifact? Independent replication required.
  • Does M1-PAM signaling produce any cognitively detectable effect in healthy young adults at sub-clinical doses? No data — and no ethical path to find out outside a trial.
  • Is the Phase 2 schiz GFAP biomarker reduction a real disease-modifying signal or a regression-to-the-mean / antipsychotic-confounded artifact? Need a longer trial with placebo-matched antipsychotic background and pre-specified GFAP analysis.
  • What is the FTD trial timeline? Anavex has had FTD orphan designation for years; an actual efficacy readout would dramatically shift the verdict.
  • Will Anavex survive the blarcamesine EMA refusal commercially? Watching the company's funding runway is part of watching this compound.
▸ Sources (full, with our context)
Back to compact view